Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

16.20 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
News headline image
3 Profitable Stocks Skating on Thin Ice
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Over the past six months, Amneal’s shares (currently trading at $6.85) have posted a disappointing 17.6% loss while the S&P 500 was down 8.1%. This might have investors contemplating their next move. 
Via StockStory
Topics Economy Government Stocks
News headline image
3 of Wall Street’s Favorite Stocks That Concern Us
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal to Report First Quarter 2025 Results on May 2, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients ↗
Amneal shares data showing Crexont improves sleep and motor symptoms in Parkinson's patients, with Phase 4 trial underway for further evaluation. 
Via Benzinga
News headline image
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars ↗
Amneal Pharmaceuticals' Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue. 
Via Benzinga
News headline image
Amneal’s (NASDAQ:AMRX) Q4 Sales Beat Estimates, Guides for Strong Full-Year Sales
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 18.4% year on year to $730.5 million. The company’s... 
Via StockStory
Topics Artificial Intelligence Earnings Intellectual Property
News headline image
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 28, 2025 ↗
 
Via Benzinga
News headline image
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know. 
Via StockStory
News headline image
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock ↗
JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million. 
Via Benzinga
News headline image
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
News headline image
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.